TherapeuticsMD focuses on developing and licensing innovative women's health products, emphasizing its commitment to addressing the unique needs of women. The company operates as a royalty company, which allows it to leverage its proprietary technologies and products through exclusive licensing agreements. This strategy enables TherapeuticsMD to expand its reach in the United States and globally, ensuring that its differentiated offerings are accessible to a broader audience.

The company's product pipeline includes notable offerings such as ANNOVERA®, BIJUVA®, and IMVEXXY®, each designed to provide effective solutions for women's health issues. These products are backed by a robust portfolio of patents, highlighting TherapeuticsMD's dedication to innovation and intellectual property protection. The company provides comprehensive prescribing information for each product, including important safety warnings, ensuring that healthcare providers and patients are well-informed about the benefits and risks associated with their use.

United States

TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their health care issues. We create products to address the unique changes and challenges women experience through every stage of their lives.

With momentum fueled by the needs of our customers, we combine entrepreneurial spirit and clinical expertise to develop innovative solutions designed to go beyond what is presently available. This includes a variety of therapies in our pipeline, along with prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands.

Urogenital Diseases

TherapeuticsMD

Menopause

Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate Reference ID: 4341448 conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and FSH, through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. Endogenous progesterone is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone enhances cellular differentiation and generally opposes the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progesterone exerts its effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, and central nervous system.

TX-001HR: BIJUVA™ (Estradiol and Progesterone)

Cancer

Contraceptive

Neuroblastoma

Spinal cord tumor

CHCs lower the risk of becoming pregnant primarily by suppressing ovulation.

 ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System)

Dyspareunia

Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and FSH, through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.

TherapeuticsMD

Company Details